Enterosys

Executive Summary

Enterosys is a French Contract Research Organization (CRO) specializing in preclinical testing of compounds targeting the gut-organ axes, including the gut-brain, gut-liver, and gut-skin connections. Founded in 2017 and headquartered in Lyon, the company leverages integrated physiology technologies to evaluate pharmaceuticals, nutraceuticals, dermocosmetics, and food/feed products. By focusing on the microbiome and its systemic effects, Enterosys addresses the growing demand for specialized preclinical services in the rapidly expanding microbiome therapeutics and diagnostics market. As a private, pre-clinical stage company, Enterosys has yet to disclose its funding or valuation, but its niche positioning in a high-growth sector positions it well for potential partnerships and service contracts with biotech and pharma companies. The company's services are critical for clients seeking to validate gut-targeted interventions, and its location in Lyon, a major European biotech hub, provides access to a skilled workforce and collaborative ecosystem. Despite limited public information, Enterosys's focus on a key area of biomedical research suggests it could be a valuable acquisition target or candidate for future funding rounds.

Upcoming Catalysts (preview)

• 2026Major Service Contract or Partnership Announcement60% success
• 2026Series A or Seed Funding Round50% success
• 2027Expansion into New Therapeutic Axes or Technologies40% success